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Installing bioactivity on metallic biomaterials by mimicking the extracellular matrix 
(ECM) is crucial for stimulating specific cellular responses to ultimately promote tissue 
regeneration. Fibronectin is an ECM protein commonly used for biomaterial 
functionalization. The use of fibronectin recombinant fragments is an attracting 
alternative to the use of full-length fibronectin due to the relatively low cost and facility 
of purification. However, it is necessary to combine more than one fragment, e.g. the 
cell attachment site (CAS) and the heparin binding II (HBII), either mixed or in one 
molecule to obtain complete activity. In the present study, we proposed to install 
adhesion capacity to the HBII fragment by an RGD gain-of-function DNA mutation 
retaining its cell differentiation capacity thereby producing a small and very active 
protein fragment. The novel molecule, covalently immobilized onto titanium surfaces 
maintained the growth factor binding capacity and stimulated cell spreading, 
osteoblastic cell differentiation and mineralization of human mesenchymal stems cells 
compared to the HBII native protein. These results highlight the potential capacity of 
gain-of-function DNA mutations in the designing of novel molecules for the 
improvement of osseointegration properties of metallic implant surfaces.
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Titanium (Ti) is the most widely used biomaterial for bone tissue implantation due to its 
good mechanical properties and biocompatibility.1 However, in some circumstances the 
stability of metallic implants is compromised due to reduced osseointegration at the 
implant-tissue interface mainly attributed to the lack of bioactivity. To overcome this 
limitation, recent studies are focused on the functionalization of Ti surface mimicking 
the natural environment of cells,2,3 this is, the extracellular matrix (ECM). The ECM is 
composed of several molecules secreted by the cells that, in addition to providing 
structural and mechanical support for tissues and interacting with cells through some 
cell-surface receptors like integrins, is able to bind soluble molecules present in the 
extracellular fluids like the growth factors,4 which are known to play a crucial role in 
tissue regeneration.
In this context, there is a growing interest in designing functionalized biomaterials that 
incorporate ECM growth factor-binding domains. This has clear advantages compared 
to the use of growth factor-based biomaterials in tissue engineering.5–7 This is because 
in the latter strategy undesired side effects difficult their clinical application8,9 whereas 
in the former strategy spatial and temporal controlled release of growth factors may 
drive tangible therapeutic effects.10
Among the different ECM proteins, fibronectin is one of the most well-known. It 
contains several domains that interact not only with cells but also with other proteins, 
mediating many cellular processes such as cell adhesion, migration, growth and 
differentiation.11 Although the use of full-length fibronectin for functionalizing Ti 
implants has demonstrated improved osteoconduction capacity,12 its use for clinical 
applications is hampered because only small fibronectin quantities can be purified from 
human plasma13 and full-length proteins are sensitive to proteolytic degradation and 
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may induce immune responses.14 An alternative strategy is the use of fibronectin protein 
fragments obtained by DNA recombinant methodologies that can be engineered 
containing active domains in small molecules that retain functionalities. In vitro and in 
vivo use of fibronectin fragments has shown much more potency than full-length 
fibronectin.15 In this regard, the cell attachment site (CAS) recombinant fragment from 
fibronectin, which encompasses at least the type III10 domain (which contains the cell 
adhesive RGD motif) and the type III9 domain (which contains the PHSRN synergistic 
sequence) has proved enhanced osseoinduction and osseintegration capacities when 
functionalized on Ti implants.16,17
Recent studies however have evidenced that the presence of heparin binding II (HBII) 
recombinant fragment from fibronectin is necessary to achieve complete activity when 
using CAS-functionalized surfaces.18,19 The HBII fragment acts as a highly promiscuous 
growth factor binding domain,20 allowing strong crosstalk between integrins and growth 
factor receptors when immobilized close to the CAS fragment.21 Thus, the combination 
of both fragments promotes higher osseoinduction compared to each fragment alone19. 
In addition, HBII fragment also plays a pivotal role in cell adhesion thorough the 
binding to Syndecan-4 cell surface heparan sulphate proteoglycan.22 This interaction 
induces focal adhesion formation and maturation only when interaction of CAS with 
integrins is present.23
Nonetheless, the simultaneous immobilization of both CAS and HBII fragments does 
not guarantee reproducibility of results because the percentage of each fragment at the 
surface cannot be controlled, due to adsorption competition.19 Alternatively, the 
generation of a single molecule containing both CAS and HBII fragments generates a 
bigger protein, which is more difficult to obtain and may be less stable after 
immobilization.
Page 4 of 43
ACS Paragon Plus Environment





























































To overcome these limitations, the aim of the present study was to functionalize the Ti 
surface with a single recombinant protein able to promote both adhesion and 
differentiation activities, in view to improve implant osseointegration. To achieve this 
objective we proposed to introduce a mutation in the HBII DNA sequence in order to 
include an RGD sequence that is expected to promote cell adhesion while retaining its 
cell differentiation properties. After the mutation, the growth factor binding capacity 
was checked measuring the interaction of the functionalized surfaces with BMP-2 and 
TGF-β1. Cellular activities of the novel protein covalently attached to Ti were evaluated 
in terms of cell adhesion, cell spreading, cell proliferation, cell differentiation and 
mineralization using human mesenchymal stem cells (hMSCs) in order to elucidate the 
osseoinduction capacity.
2. MATERIALS AND METHODS
2.1. Titanium Samples
Commercially pure Ti grade 2 discs of 10 mm diameter and 2 mm thickness were 
grinded with silicon carbide papers of grit 320, 800, 1200 and 2500 (Struers, Spain). 
Then, the discs were mirror polished with colloidal silica (0.05 µm particle size) and 
ultrasonically cleaned with cyclohexane, isopropanol, deionized water, ethanol and 
acetone (3 x 5 min each).
2.2. Synthesis of Recombinant Fibronectin Fragments
Human fibronectin fragments CAS, spanning the 8-10th type III repeats, and HBII, 
spanning the 12-14th type III repeats, were produced by standard recombinant DNA 
methodologies as previously described.19 Briefly, each DNA fragment was inserted into 
a pGEX-6-P1 plasmid (GE Healthcare, UK) and separately amplified in DH5α cells 
(Invitrogen, USA). After purifying and sequencing, correct constructs were separately 
inserted in BL21 cells (New England BioLabs, UK) and the resulting colonies were 
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dynamically cultured in LB broth containing 100 µg/ml ampicillin at 37ºC. Protein 
production was induced by isopropyl β-D-1-thiogalactopyranoside (IPTG; 1mM final 
concentration) during 4h at 37ºC. Cells were harvested by centrifugation, resuspended 
and sonicated. After removing cell fragments and insoluble proteins by centrifugation 
proteins were purified using a GSTrap affinity column (GE Healthcare). GST-tag was 
removed on-column and purified fragments were resolved by electrophoresis. Protein 
concentrations were quantified by BCA method following the manufacturer’s 
instructions (Thermo Fisher Scientific, USA). 
2.3. RGD-point Mutation
Two missense mutations were generated in the HBII construct to introduce an RGD 
motif (RGD-mutated HBII fragment; Figure 1) by using the Quickchange Lightning 
site-directed mutagenesis kit (Agilent Technologies, USA). Mutagenesis reactions were 
performed in a T100 thermal cycler (Bio-Rad, USA) according to the manufacturer’s 
guidelines. DNA primers for the P233R mutation were 5’-CT CGG CCC CGC CGT 
GGT GTC ACA GA-3’ (forward) and 5’-TC TGT GAC ACC ACG GCG GGG CCG 
AG-3’ (reverse). Plasmids containing the mutation were transformed into DH5α cells, 
purified and sequenced. Correct plasmids were mutated in a second round using 5’-CC 
CGC CGT GGT GAC ACA GAG GCT AC-3’ (forward) and 5’-GT AGC CTC TGT 
GTC ACC ACG GCG GG-3’ (reverse) primers for the V235D mutation. Constructs 
were transformed into DH5α cells, purified and sequenced. Details on gene sequencing 
and the resulting mutated sequence are shown in Supporting Information. Correct 
constructs were transformed into BL21 cells and RGD-mutated HBII fragments were 
produced and purified as explained above. 
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The molecules were covalently attached to Ti discs by silanization as carefully 
described in previous studies.19,24 Briefly, Ti discs were cleaned and activated by 
oxygen plasma for 5 min at 12 MHz in a Femto low pressure plasma system (Diener 
electronic, Germany). Then, samples were immersed in 0.08 M solution of (3-
aminopropyl)triethoxysilane (APTES, Sigma-Aldrich) at 70ºC for 1h, rinsed with 
different solvents and cross-linked with 7.5 mM solution of N-succinimidyl-3-
maleimidepropionate (SMP). Finally, fibronectin recombinant fragments were 
immobilized on Ti surface at a 100 µg/ml concentration (optimized in previous studies 
by our group19)  in phosphate-buffered saline (PBS) to ensure saturation of the surface. 
Uncoated polished Ti discs and fibronectin-coated discs were used as negative and 
positive controls, respectively. Discs functionalized with 70% CAS and 30% HBII 
(CAS70:HBII30) were also used as positive controls considering the results obtained in 
a previous study.19
2.5. Functionalization Characterization
2.5.1. Surface Chemical Composition
The chemical composition (atomic percentage) at the surface level was measured by X-
ray photoelectron spectroscopy (XPS; SPECS Surface Nano Analysis GmbH, Germany) 
to determine the presence of RGD-mutated HBII fragment after immobilization. Spectra 
of samples were acquired with a non-monochromatic Mg anode XR50 source operating 
at 150 W and a Phoibos 150 MCD-9 detector. Detector pass energy was fixed at 25 eV 
with 0.1 eV steps to record high resolution spectra at a pressure below 7.5 × 10−9 mbar. 
Peak fittings and spectral analysis were performed using CasaXPS software (version 
2.3.16, Casa Software Ltd., UK). All binding energies were calibrated with the C 1s 
signal located at 284.8 eV.
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2.5.2. Biomolecule Density at the Surface
The adsorption kinetics of the RGD-mutated HBII fragment on Ti surface was evaluated 
by quartz crystal microbalance with monitoring dissipation (QCM-D). For this assay, 
TiO2 sensors (QSX310, Q-Sense, Sweden) were silanized and coated as described above 
for Ti discs. Measurements were performed at 37ºC by monitoring changes in 
frequency, Δf (Hz), and dissipation, ΔD (×10−6), in real-time using Qsoft software (Q-
Sense) in a D300 equipment (Q-Sense). First, PBS was used to completely stabilize the 
baseline during 30-60 min and then the biomolecule was injected at 100 µg/ml in PBS 
monitoring its adsorption during 280 min. Finally, weakly bound biomolecules were 
rinsed with PBS for 30 min. All raw data was analyzed using QTools software (Q-
Sense) to obtain surface mass density and thickness values.
2.6. Determination of Integrin and Growth Factor Binding Capacity
The capacity of the biomolecules to bind growth factors was evaluated by QCM-D. To 
this end, Ti sensors were coated with CAS, HBII or RGD-mutated HBII as described in 
the previous section and blocked injecting 100 µg of bovine serum albumin (BSA) in 
PBS to prevent non-specific protein interactions. After the baseline was stabilized, non-
attached BSA was removed by rinsing in PBS for 10 min and 1 µg of BMP-2 or TGF-β1 
(Peprotech, USA) were injected. Finally, non-attached growth factors were removed by 
rinsing with PBS for 10 min. Increases in surface mass density were quantified using 
QTools software (Q-Sense).
To determine the capacity of the different molecules to bind integrin α5β1 and BMP-2, 
an ELISA experiment was performed on Ti functionalized samples.  To this end, Ti 
discs were functionalized as above described with 100 μg/ml of CAS, HBII or HBII-
RGD fragments. The discs were rinsed thrice in 0.01% Tween-20 in PBS (PBS-T) and 
incubated with blocking buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM CaCl2, 
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1 mM MgCl2, 1 mM MnCl2 and 1% BSA) for 1h. Samples were washed thrice in PBS-
T and incubated with different concentrations of integrin  α5β1 (ranging from 0 to 100 
nM; R&D Systems, USA) or BMP-2 (ranging from 0 to 400 nM; Peprotech) for 2h. 
Afterwards, samples were washed four times in PBS-T  and incubated with rabbit anti-
integrin β1 (1:300; Thermo Fisher Scientific) or goat anti-BMP-2 (1:100; Santa Cruz 
Biotechnologies) for 1h. After five washes in PBS-T, samples were incubated with goat 
anti-rabbit immunoglobulins/HRP or rabbit anti-goat immunoglobulins/HRP (1:2000; 
Agilent Dako, USA) for 1h. Samples were then washed five times in PBS-T and 
detection was performed by incubating in 100 μl of 3,3’,5,5’-tetramethylbenzidine 
(TMB; Sigma-Aldrich) substrate solution for 10 min before stopping the enzymatic 
reaction by adding 100 μL 1NH2SO4. Colorimetric intensity was then measured at 450 
nm in a Synergy HTX multi-mode reader (Bio-Tek).
The capacity of the novel RGD-mutated HBII molecule to bind at the same time integrin 
α5β1 and BMP-2 was evaluated following a variation of the ELISA protocol. Samples 
functionalized with CAS, HBII or HBII-RGD were blocked, incubated with 50 nM 
integrin α5β1 (saturating concentration determined in the previous ELISA) for 2h and 
then incubated with 100 nM BMP-2 solution for 2h. Samples were incubated with goat 
anti-BMP-2 and rabbit anti-goat immunoglobulins/HRP before adding TMB. The 
binding of BMP-2 after incubating the samples with integrin α5β1 was measured at 450 
nm as above described.
2.7. Mesenchymal Stem Cell Response
2.7.1. Cell Culture
Human bone marrow mesenchymal stem cells (hMSCs; Tebu-bio, France) were 
cultured in Advanced DMEM supplemented with 10% foetal bovine serum (FBS), 20 
mM HEPES buffer solution, penicillin/streptomycin antibiotics (50 U/ml and 50 µg/ml, 
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respectively) and 2 mM L-glutamine (all from Thermo Fisher Scientific) at 37ºC in a 
humidified atmosphere and 5% CO2. Cells from passage 4 were used in all the 
experiments.
2.7.2. Cell Adhesion and Proliferation
Cells were seeded in serum-free conditions at a concentration of 10000 cells/sample and 
allowed to adhere for 4 h. Then, medium was aspirated and cells were cultured for 28 
days in complete medium containing FBS changing the medium thrice a week. After 
each incubation period (4 h, 3 days, 7 days, 14 days, 21 days and 28 days), cells were 
rinsed thrice in PBS and lysed with 300 µl of Mammalian Protein Extraction Reagent 
(M-PER, Thermo Fisher Scientific). The number of living cells adhered at samples was 
measured quantifying the released lactate dehydrogenase (LDH) activity after lysis 
using the Cytotoxicity Detection KitPLUS (LDH) (Roche, USA). Obtained absorbances at 
492 nm in a Synergy HTX multi-mode reader (Bio-Tek, USA) were expressed as cell 
number using a calibration curve with increasing numbers of cells.
2.7.3. Cell Spreading and Adhesion Interaction
Cells (25000 cells/sample) were seeded in serum-free medium in each sample and after 
4 h fixed with 4% paraformaldehyde (PFA) for 20 min. Then cells were permeabilized 
with 0.05% Triton X-100 in PBS for 15 min and washed thrice with 20 mM glycine in 
PBS (washing buffer). Samples were blocked with 1% BSA for 30 min to prevent non-
specific protein interaction. For the cell spreading assay, cells were incubated with 
mouse antivinculin antibody (1:100) for 1 h, rinsed with washing buffer and incubated 
with Alexa Fluor 488 goat antimouse antibody (1:1000) and Alexa Fluor 546 phalloidin 
(1:300) in the dark for 1 h. For the adhesion interaction assays, cells were incubated 
with mouse anti-syndecan-4 (1:100; Santa Cruz Biotechnologies) and rabbit anti-
integrin β1 (1:300) antibodies for 1h, rinsed with washing buffer and incubated with 
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Alexa Fluor 488 chicken anti-rabbit and Alexa Fluor 568 goat anti-mouse (1:1000) 
antibodies in the dark for 1 h. After antibodies incubation, nuclei were counterstained 
with DAPI (1:1000) and samples mounted in Mowiol 4-88 (Sigma-Aldrich, USA) 
before visualizing in an LSM 800 confocal laser scanning microscope (Carl Zeiss, 
Germany). For the spreading assay, at least five images from different areas at 10× 
magnification of each sample were acquired and the area of cells was calculated using 
the ImageJ software (National Institute of Health, USA). For the adhesion interaction 
assay, image stitching of 3 x 3 images at 63× magnification was performed.
The amount of integrin β1 and syndecan-4 expressed by cells was quantified by western 
blot analysis. To this end, cells were seeded in triplicate (30000 cells/sample) as 
explained above and allowed to adhere for 4h. Then, cells were lysed in RIPA buffer (50 
mM Tris-HCl pH 7.6, 150 mM NaCl, 0.25% sodium deoxycholate, 0.1% SDS, 1 mM 
EDTA, plus protease inhibitors; Sigma-Aldrich) and centrifuged at 12.000 g for 10 min. 
Equal amounts of proteins were size-fractioned in SDS-PAGE under reducing 
conditions (100V, 2h) and transferred to nitrocellulose membranes (60V, overnight). 
Membranes were blocked with 10% BSA in PBS-T and incubated with mouse anti-β-
actin (1:500; Santa Cruz Biotechnologies), rabbit anti-integrin β1 (1:300; Thermo Fisher 
Scientific) or mouse anti-syndecan-4 (1:100; Santa Cruz Biotechnologies) overnight at 
4ºC. After several washes in PBS-T, membranes were incubated with goat anti-rabbit 
immunoglobulins/HRP or goat anti-mouse immunoglobulins/HRP (Agilent Dako) and 
detection was performed with luminol reagent (Santa Cruz Biotechnologies). Bands 
were quantified with the Quantity One Quantitation Software (Bio-Rad, USA) on 
unsaturated x-ray films. Results were normalized versus the signal obtained for β-actin.
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The alkaline phosphatase (ALP) activity was quantified using the same extracts 
obtained from the proliferation assay by a SensoLyte pNPP Alkaline Phosphatase 
Activity Kit (AnaSpech Inc., USA). ALP levels were obtained after extrapolating the 
absorbances obtained at 405 nm using a Synergy HTX multi-mode reader (Bio-Tek) to a 
calibration curve prepared following the manufacturer’s instructions. Results were 
normalized versus their corresponding cell numbers obtained in the cell proliferation 
assay.
The expression of genes related to osteogenic differentiation was evaluated by real time 
quantitative polymerase chain reaction (RT-qPCR). Cells were cultured at a density of 
25000 cells/sample on Ti discs functionalized with HBII or RGD-mutated HBII 
fragments and allowed to adhere for 4 h in serum-free medium. Non-functionalized Ti 
was used as control substrate. Then, cells were incubated for additional 2 h in serum-
free medium with or without 25 ng/ml of BMP-2. After removing the medium, cells 
were incubated in serum-free medium until 24 h after cell seeding. Then, FBS was 
added and cells cultured for 7 days changing the medium every two days. After each 
incubation period (1 day, 3 days and 7 days), total RNA was extracted and purified 
using the RNeasy Mini Kit (Qiagen, Germany). Equal amounts of RNA (100 ng), 
quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 
USA), were retrotranscribed to cDNA using the QuantiTect Reverse Transcription Kit 
(Qiagen). RT-qPCR analyses were performed using the QuantiTect SYBR Green RT-
PCR Kit (Qiagen) and specific primers (Table 1) in a StepOnePlus Real-Time PCR 
System (Applied Biosystems, USA). The fold change of gene expression was obtained 
after normalizing the values to Ti without BMP-2 at day 1 and to β-actin. Detailed 
protocol and calculations has been described elsewhere.25
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Acc. Number Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) Amplicon 
size (bp)























NM_199173.5 TGAGAGCCCTCACACTCCTC ACCTTTGCTGGACTCTGCAC 98
2.7.5. Cell Mineralization
Cells were seeded in the same conditions described for the cell proliferation assays for 
14, 21 and 28 days. Then, cells were fixed with 4% PFA for 15 min and washed twice 
with Milli-Q water. Calcium deposits were stained with 500 µl/sample of 40 mM 
Alizarin Red S (Sigma-Aldrich) for 20 min with gently shaking. After removing excess 
dye with several Milli-Q water washings, stained surfaces at 28 days of culture were 
examined using an Olympus BX51-P microscope (Olympus Corp., Japan). Afterwards, 
10% cetylpyridinium chloride in 10 mM NaH2PO4 was added to extract the staining. 
Supernatants were then collected and spectrophotometrically measured at 570 nm in a 
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Synergy HTX multi-mode reader (Bio-Tek). Results were normalized versus their 
corresponding cell numbers obtained in the cell proliferation assay.
2.8. Statistical Analysis
All data are presented as mean values ± standard error of the mean. Experiments were 
performed in triplicate using in each one three replicates per each group. Statistically 
significant differences between groups (p-value < 0.05) were analyzed by Kruskal-
Wallis non-parametric test followed by Mann-Whitney test with Bonferroni correction 
using the SPSS statistics software (IBM, USA).
3. RESULTS
An RGD sequence was included in the HBII protein sequence by modifying the DNA 
sequence with two missense mutations (see Materials and Methods). The mutations 
were produced in a loop in the FN III14 domain (Figure 1A) which is closely similar to 
the RGD loop in the CAS domain in order to be sensed by cells. Herein, a PGV amino 
acid sequence was mutated to RGD by modifying only two nucleotides (Figure 1B).
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Figure 1. RGD mutation in the HBII domain of fibronectin. (A) Stereoview of the 
folding topology of the native HBII fragment of fibronectin (top). The structure is 
represented as a cartoon with the β-strands shown as arrows. The sequence PRRARV in 
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FN III13, responsible of the heparin binding activity has been highlighted. The Pro233-
Gly234-Val235 (PGV) sequence in FN III14 has been mutated into Arg233-Gly234-
Asp235 (RGD). Lysine residues, which participate in the covalent attachment to Ti, are 
highlighted with red circles. Linear amino acid sequence of the HBII fragment of 
fibronectin (bottom). The β-strands are represented by arrows and the type III repeats 
are highlighted with different colours. The mutated amino acids to generate and RGD 
sequence are highlighted in red. (B) Stereoview of the folding topology of the native 
CAS fragment of fibronectin (top) and linear amino acid sequence (bottom). Lysine 
residues, which participate in the covalent attachment to Ti, are highlighted with red 
circles. The RGD sequence is highlighted in red.
3.1. Characterization of the Titanium Functionalization
The presence of RGD-mutated HBII fragment at the Ti surface was analyzed measuring 
the surface elemental composition by XPS. A decrease of both Ti 2p and O 1s was 
observed after silanization which was also observed after functionalization (Table 2). 
Silanization with APTES also produced an increase in the Si 2p, N 1s and C1s. Presence 
of N was attributed to the imide group of the SMP crosslinker. The addition of RGD-
mutated HBII fragment produced a further increase in N 1s and C 1s and a considerable 
decrease in Si 2p. This increase of N can be attributed to the peptide bonds and amino 
acid side chains.
Table 2. Surface elemental composition (atomic percentages).
Ti 2p O 1s Si 2p N 1s C 1s
Ti 13.52 (±0.51) 48.18 (±5.93) 0.61 (±0.16) 1.06 (±0.17) 35.65 (±6.44)
Silanized Ti 0.49 (±0.50) 26.27 (±1.73) 12.94 (±0.52) 8.31 (±0.09) 51.70 (±1.80)
Sil. Ti + RGD-mut. HBII 0.79 (±0.06) 20.43 (±0.17) 3.89 (±0.13) 14.41 (±0.29) 60.47 (±0.05)
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In addition, the presence of RGD-mutated HBII recombinant fragment on the Ti surface 
was quantified using QCM-D. After rinsing with PBS, the thickness and surface mass 
density values of the adlayer of immobilized molecule on silanized Ti sensors were 
close to CAS and HBII values obtained in a previous study (Table 3).19 Changes in 
frequency and dissipation recorded during the adsorption of RGD-mutated HBII 
fragment are shown in Figure 2A and 2B, respectively. It can be noted that the 
frequency rapidly decreased after injection and, after rinsing with PBS, the values were 
stabilized.
Table 3. Thickness and surface mass density of the bound biomolecules to silanized 
Ti sensors characterized by quartz crystal microbalance with dissipation (QCM-D) 
monitoring. *CAS and HBII values were obtained in a previous study.19
Biomolecule Thickness Surface mass density (ng/cm2)
CAS 5.54 (±0.09)* 609.14 ( 10.19)*
HBII 7.49 (±0.13)* 823.80 ( 14.00)*
RGD-mutated HBII 5.08 (±0.25) 559.90 ( 27.5)
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Figure 2. Adsorption kinetics of the RGD-mutated HBII fragment on TiO2 sensors. 
Frequency shift (A) and dissipation shift (B) versus time plots of RGD-mutated HBII 
fragment immobilized on silanized TiO2 sensors using QCM-D. (C) Representative 
illustration of the growth factor binding assay performed using a QCM-D. TiO2 sensors 
were coated with CAS, HBII or RGD-mutated HBII fragments, rinsed in PBS and 
blocked with BSA. After rinsing, BMP-2 or TGF-β1 were injected and changes in the 
frequency of vibration were registered as increases in surface mass density.
3.2. Integrin and Growth Factor Binding Capacity
The interaction of the growth factors with the fibronectin recombinant fragments 
immobilized on Ti sensors was quantified using the QCM-D. A detailed illustration of 
the process is represented in Figure 2C. An increase in the surface mass density was 
observed when the Ti sensors functionalized with HBII fragment were exposed to TGF-
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β1 or BMP-2 containing solutions (Table 4). This was not observed for the CAS-
functionalized Ti sensors, which presented a slight decrease in the surface mass density. 
Interestingly, a considerable increase in the surface mass density was observed in the 
surfaces functionalized with RGD-mutated HBII fragment compared to native HBII 
fragment exposed to TGF-β1 containing solutions. In contrast, when RGD-mutated 
coated sensors were exposed to BMP-2 solutions the values were lower compared to 
HBII fragment, although they were positive.
Table 4. Increases in the surface mass density after depositing TGF-β1 or BMP-2 
onto functionalized Ti sensors.
Molecules ∆ Surface mass density (ng/cm2) 
HBII + TGF-β1 7.04 (± 0.03)
CAS + TGF-β1 -40.26 (± 0.13)
HBII-RGD + TGF-β1 116.49 (± 2.45)
HBII + BMP-2 30.36 (± 0.16)
CAS + BMP-2 -2.31 (± 0.06)
HBII-RGD + BMP-2 14.19 (± 0.09)
The capacity to bind integrin α5β1 and BMP-2 was also evaluated by ELISA. No 
binding of integrin α5β1 to native HBII was detected, since the absorbance values in all 
the integrin α5β1 concentrations were always close to the background (data not shown). 
Addition of RGD into the HBII sequence provided this fragment with the ability to bind 
integrin α5β1, although at lower levels compared to the CAS fragment (Figure 3A). 
Regarding the BMP-2 binding capacity, the HBII-RGD fragment showed lower levels 
compared to the native HBII fragment (Figure 3B). However, the absorbance levels 
showed a high level of binding to HBII-RGD fragment compared to CAS fragment, in 
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which absorbance values were close to the background for all the tested BMP-2 
concentrations (data not shown).
Figure 3. Determination of the interaction of fibronectin fragments with integrin α5β1 
and BMP-2. Dose response curves for integrin α5β1 (A) and BMP-2 (B) and absorbance 
levels (C) for BMP-2 incubated on functionalized samples after binding with (+ ITG 
α5β1) or without (- ITG α5β1) integrin α5β1.
The capacity of the HBII-RGD molecule to bind at the same time integrin α5β1 and 
BMP-2 molecules was determined by ELISA. To this end, the functionalized surfaces 
were incubated with saturating integrin α5β1 concentrations determined from Figure 3A 
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(50 nM) and afterwards incubated with a BMP-2 concentration that gave high levels in 
Figure 3B (100 nM). No binding of BMP-2 was observed in CAS-functionalized 
surfaces (Figure 3C). In contrast, no significant differences on the levels of BMP-2 
binding were observed for HBII and HBII-RGD functionalized surfaces with or without 
the previous incubation with integrin α5β1. Nonetheless, as above mentioned, the levels 
were lower for the HBII-RGD compared to native HBII.
3.3. Mesenchymal Stem Cell Response
Cells were completely spread on Ti surfaces functionalized with either full-length 
fibronectin or with the CAS fragment, presenting well-developed actin stress fibers and 
focal adhesion formation (Figure 4A and 4B). Nonetheless, whereas such focal 
adhesions were homogenously distributed in the fibronectin-coated surfaces, in those 
functionalized with the CAS fragment vinculin spots were mostly observed at the edges 
of cells. In contrast, in the HBII functionalized surfaces the cells were round with poorly 
organized actin filaments and no sign of focal adhesions, presenting also high amount of 
filopodia extensions. Interestingly, the behaviour of the cells on CAS70:HBII30 
functionalized Ti surfaces was a combination of the patterns observed in full-length 
fibronectin, CAS and HBII fragments. The presence of RGD in the HBII domain did not 
allow complete spreading of cells, but seemed to stimulate the formation of focal 
adhesions at the edges of cells, where filopodia were spikier compared to HBII. In 
addition, formation of immature actin filaments was observed in RGD-mutated HBII 
condition. The cells were completely round, with no detection of actin filaments and 
vinculin staining when cultured on bare Ti samples.
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Figure 4. Cell adhesion on the different functionalized surfaces. Representative (A) low 
magnification (10x) and (B) high magnification (63x) images of hMSCs spreading and 
morphology after 4 h of adhesion on functionalized Ti with fibronectin (FN), CAS, 
HBII, CAS70%:HBII30% (CAS70:HBII30), RGD-mutated HBII (HBII-RGD) and non-
functionalized Ti (Ti). Scale bare denotes 50 µm and 10 µm, respectively. Area (C), cell 
number (D) and circularity (E) of hMSCs adhered after 4 h of culture on the different 
functionalized Ti surfaces. Letter a indicates statistically significant differences 
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compared to FN, letter b indicates statistically significant differences compared to CAS, 
letter c indicates statistically significant differences compared to HBII, letter d indicates 
statistically significant differences compared to RGD-mutated HBII (HBII-RGD) and 
letter e indicates significant differences compared to CAS70%-HBII30% (p < 0.05).
The differences observed in morphology were quantified by measuring the area of cells 
(Figure 4C). The highest cell spreading was observed in fibronectin surfaces whereas 
the lowest values were observed on bare Ti, which were the positive and negative 
controls respectively. Interestingly, the presence of RGD in the HBII domain stimulated 
cell spreading compared to native HBII, presenting intermediate values within CAS and 
HBII and very close to CAS70:HBII30. In contrast, circularity values were in opposite 
direction. The highest value was observed for cells cultured on Ti, whereas the lowest 
value was obtained on FN coated surfaces (Figure 4D). Noteworthy, RGD mutation on 
the HBII fragment reduced the circularity values compared to native HBII fragment, 
presenting comparable values to CAS-coated surfaces. Interestingly, the number of 
adhered cells was similar in all the functionalized surfaces, with no statistically 
significant differences between all groups, except bare Ti (Figure 4E).
The interaction of hMSCs with the RGD motif produced in the RGD-mutated HBII 
fragment was evaluated by staining the proteins involved in cell adhesion, i.e. integrin 
β1 and syndecan-4 (Figure 5A and 5B). Both integrin β1 and syndecan-4 were detected 
on the fibronectin and CAS70:HBII30 functionalized surfaces. However, whereas in 
presence of fibronectin all cells presented homogeneous staining throughout the 
membrane, in CAS70:HBII30 functionalized surfaces only some cells presented diffuse 
staining. In contrast, cells cultured on CAS or HBII functionalized surfaces were 
completely stained with either only integrin β1 or only syndecan-4, respectively. 
Interestingly, the presence of RGD in the RGD-mutated HBII functionalized samples 
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stimulated the clustering of integrin β1 molecules, which were only noticed at the 
extended filopodia.
Figure 5. Expression of integrin β1 and syndecan-4 by cells cultured on the different 
functionalized surfaces. Stitching (A) and high magnification (B) immunofluorescence 
images of integrin β1 (green) and syndecan-4 (red) of hMSCs cultured on fibronectin 
(FN), CAS, HBII, CAS70%-HBII30% (CAS70:HBII30), HBII-RGD and titanium (Ti) 
surfaces. Scale bar denotes 50 μm and 10 μm, respectively. Representative images for 
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the western blot detection (C) and quantification of integrin β1 (D) and syndecan-4 (E). 
Letter a indicates statistically significant differences compared to FN, letter b indicates 
statistically significant differences compared to CAS, letter c indicates statistically 
significant differences compared to HBII, letter d indicates statistically significant 
differences compared to RGD-mutated HBII (HBII-RGD) and letter e indicates 
significant differences compared to CAS70%-HBII30% (p < 0.05).
The amount of integrin β1 and syndecan-4 proteins expressed by cells was quantified by 
western blot (Figure 5C). Integrin β1 levels were higher on cells cultured on FN and 
CAS compared to cells cultured on the other surfaces (Figure 5D). Interestingly, the 
presence of RGD on HBII stimulated the expression of integrin β1. Syndecan-4 was 
expressed by cells cultured on all the functionalized surfaces except on CAS (Figure 
5E).
The capacity of hMSCs to proliferate on the different functionalized substrates was 
studied after culturing cells for 3, 7, 14, 21 and 28 days (Figure 6A). The molecules 
containing the CAS domain (i.e. fibronectin and CAS) stimulated the highest values of 
proliferation at 21 days, whereas HBII domains including the RGD-mutated HBII 
domain produced lowest cell proliferation values, equivalent to uncoated Ti.
Opposite trends were observed for the ALP activity values (Figure 6B). The highest 
values were obtained when hMSCs were cultured onto HBII and RGD-mutated HBII 
functionalized Ti surfaces. Noteworthy, when comparing both functionalizations, the 
RGD-mutated HBII stimulated statistically significant higher ALP production at 28 
days. In contrast, hMSCs produced lower ALP quantities when cultured on surfaces 
functionalized with CAS, fibronectin and non-functionalized Ti. CAS70:HBII30 
presented intermediate values between HBII and CAS containing fragments.
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Figure 6. Cell proliferation and differentiation on the different functionalized surfaces. 
LDH (A) and ALP (B) activity of cells cultured on the different functionalized Ti 
surfaces for 3 days, 7 days, 14 days, 21 days and 28 days. At each time point, letter a 
indicates significant differences compared to FN, letter b indicates significant 
differences compared to CAS, letter c indicates significant differences compared to 
HBII, letter d indicates significant differences compared to RGD-mutated HBII (HBII-
RGD) and letter e indicates significant differences compared to CAS70-HBII30 (p < 
0.05).
Cell differentiation was also evaluated by measuring the expression of genes related to 
osteogenesis. In general, similar trends were observed for all the analyzed genes (Figure 
7). Specifically, the ALP, BMP-2, RUNX2 and OCN gene expression values 
considerably increased when cells were cultured for 1 day on HBII functionalized 
Page 26 of 43
ACS Paragon Plus Environment





























































surfaces in absence of BMP-2 compared to control substrate (Ti). Noteworthy, the 
observed increase for all genes at 1 day was higher when cells were cultured on RGD-
mutated HBII functionalized Ti surfaces in absence of BMP-2 in the medium compared 
to native HBII fragment. Then, gene expression levels notably decreased in both HBII 
and RGD-mutated HBII surfaces, excepting OCN that slowly decreased during cell 
culture time. Interestingly, when cells were cultured for 2 h with BMP-2 the gene 
expression levels for all the analyzed genes increased at 1 day of culture in both HBII 
and RGD-mutated HBII functionalized Ti surfaces compared to results obtained in 
absence of BMP-2. At day 3 and day 7 gene expression values also decreased to control 
levels, presenting OCN slower decreases. In contrast, the values for all genes in cells 
cultured on Ti were similar during all the cell culture time in absence of BMP-2, 
observing no significant increases. Conversely, gene expression for BMP-2, RUNX2 
and OCN slightly increased on Ti when cells were cultured in presence of BMP-2.
Figure 7. Gene expression levels for ALP (A), BMP-2 (B), RUNX2 (C) and OCN (D) 
of hMSCs cultured with or without BMP-2 on control surfaces (Ti) or HBII or RGD-
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mutated HBII functionalized surfaces for 1, 3 and 7 days. Results were normalized 
versus β-actin and are represented as relative fold change compared to Ti without BMP-
2 at day 1. At each time point, letter a indicates significant differences compared to FN, 
letter b indicates significant differences compared to CAS, letter c indicates significant 
differences compared to HBII, letter d indicates significant differences compared to 
RGD-mutated HBII (HBII-RGD) and letter e indicates significant differences compared 
to CAS70-HBII30 (p < 0.05). Two letters indicate p < 0.01 and three letters indicate p < 
0.001.
The capacity of the different functionalized Ti surfaces to induce mineralization was 
evaluated by quantifying the deposition of calcium by Alizarin Red staining (Figure 8). 
The highest levels were observed for the surfaces containing the HBII fragment, i.e. 
RGD-mutated HBII, HBII and CAS70-HBII30. Noteworthy, the highest staining values 
were observed in cells cultured on RGD-mutated HBII surfaces, being almost three 
times higher (Figure 5D and 5E). The mineralization levels were lower in CAS and FN 
surfaces compared to surfaces containing the HBII fragment, bare Ti surfaces presenting 
the lowest values.
Figure 8. Mineralization of cells cultured on the different functionalized surfaces. 
Quantification of calcium deposits (A) produced by hMSCs on the different 
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functionalized Ti surfaces after extracting Alizarin Red staining at 14, 21 and 28 days of 
culture. Results were normalized versus their corresponding cell numbers. 
Representative optical microscopy images (B) acquired at 28 days of culture. At each 
time point, letter a indicates significant differences compared to FN, letter b indicates 
significant differences compared to CAS, letter c indicates significant differences 
compared to HBII, letter d indicates significant differences compared to RGD-mutated 
HBII (HBII-RGD) and letter e indicates significant differences compared to CAS70-
HBII30 (p < 0.05).
4. DISCUSSION
Mutations are naturally occurring changes in the DNA genomic sequence that can lead 
to alterations in protein functions. Since mutation events introduce random genetic 
changes, most of the time they result in loss of function. It is therefore not surprising 
that in most cases mutations are associated with a negative process, such as cancer. 
These loss-of-function mutations are traditionally used in the laboratory for impairing 
protein functionality or identifying functional sequences. Nonetheless, sometimes the 
random change by pure chance confers some new function on the gene. These gain-of-
function mutations may provide selective advantages that are the engine of evolution. 
Herein, we proposed to produce a gain-of-function directed mutation to generate a novel 
protein with dual activities to promote osteogenesis: stimulate cell adhesion and cell 
differentiation simultaneously. For this purpose, the HBII fragment was selected for its 
well-known ability to sequester growth factors20 that, in the end, stimulate cell 
differentiation into the osteoblastic lineage. Initially, we identified several regions where 
an RGD sequence, which should confer cell adhesion properties to the HBII domain, 
could be introduced by minimally modifying the DNA sequence (i.e. only two point 
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mutations). In turn, such mutation should not alter or affect important sequences in the 
HBII protein structure. 
The HBII domain consists of three type III repeats (III12,13,14) of 90 amino acids each. 
Heparin binding activity is mainly located in the type III13 repeat,26,27 specifically in the 
sequence PRRARV defined as heparin-binding consensus sequence X-B-B-X-B-X 
where B is a basic residue and X is a hydrophobic residue.28 Heparin interacts with 
fibronectin mainly at this sequence and is involved in the interaction with other proteins 
containing heparin-binding domains, including growth factors, thereby acting as 
reservoir that is dynamically remodelled as cellular requirements change.29,30 In the 
present work we did not want to affect the main activity of the HBII domain, thereby the 
type III13 repeat was avoided in the mutation design. 
Among the other two type III repeats of the HBII domain, we identified a loop in the 
III14 that is closely similar to the loop on the CAS domain III10 (where RGD is present, 
Figure 1B top and bottom) that could be sensed by cells. Therein, we modified only two 
nucleotides (Figure S1) to produce a change in the protein sequence from PGV to RGD 
(Figure 1A top and bottom). In addition, considering that silanization mainly occurs 
through lysine (K) residues and most of them are opposite to the RGD mutation (Figure 
1A top), we assumed that the generated RGD sequence is exposed and available for 
cells to interact. In fact, this was corroborated by the capacity of the novel protein 
fragment to bind integrin α5β1. Although only two amino acids were modified in the 
HBII domain, which is approximately 300 amino acids long, those changes may 
produce structural alterations in the tertiary structure of the recombinant protein. 
Obviously, this modification was far enough not to affect the main heparin-binding 
activity located at the III13 module, but might affect other HBII properties. Apart from 
the heparin-binding activity attributed to PRRARV in the III13 module, it has been 
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recently observed that HBII binds a huge panel of growth factors with moderately high-
affinity in a heparin-independent manner.20 This property is very attractive for the 
design of smart materials that allow reducing growth factor doses while improving their 
safety.31,32 Although growth factors are potent regenerative biomolecules, there are still 
concerns on their medical use mainly due to undesired side effects. For instance, BMP-2 
is the only Food and Drug Administration (FDA)-approved osteoinductive growth factor 
used in biomaterials, although it may mediate postoperative inflammation, ectopic bone 
formation and/or osteoclast-mediated bone resorption.9,33 Therefore, the use of 
biomaterials functionalized with biomolecules, e.g. HBII, that sequester and release in a 
controlled manner endogenous growth factors could be of paramount interest for 
restoring tissue functions without side effects. For the specific case of HBII, it has been 
demonstrated that co-presentation with CAS fragment (containing at least type III9-10 
modules) is required to achieve optimal in vitro and in vivo responses.18,19 However, 
both fragments engineered in one molecule generate a big protein that could be more 
sensitive to proteolytic degradation. The rationale in the present study was to generate a 
small molecule containing both cell adhesion (i.e. RGD mutation) and cell 
differentiation (i.e. growth factor retention) capacities.
The specific sequences of the HBII fragment of fibronectin responsible for the growth 
factors binding capacity in a heparin-independent manner remain currently undefined. In 
fact, there are no evidences that the PRRARV is responsible for this growth factor 
binding capacity in absence of heparin. For this reason, after mutating the DNA 
sequence of the HBII domain, we wanted to check if the recombinant protein still 
retained its growth factor binding capacity. To this end, we used BMP-2 and TGF-β1 as 
growth factor models due to their important roles in osteogenesis processes. Both 
growth factors signalling transduction converges at the Runx2 gene to control 
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mesenchymal precursor cell differentiation.34–36 We observed that the novel protein still 
retains the capacity to bind both BMP-2 and TGF-β1 although the presence of RGD 
modified to some extent the growth factor binding capacity of native HBII. Specifically, 
a slightly decrease in BMP-2 and a considerable increase in TGF-β1 binding capacity 
was observed. Interestingly, binding of BMP-2 was not affected by the previous 
bonding with integrin α5β1 in the HBII-RGD protein fragment as observed by ELISA, 
which demonstrate that the novel molecule is capable to bind at the same time integrin 
α5β1 and BMP-2, although the HBII fragment is a relatively small molecule 
(approximately 30 kDa). This is possible considering the fact that not all the molecule is 
necessary for protein-protein interaction, as it occurs for instance between BMP-2 and 
its receptors. The alteration in BMP-2 and TGF-β1 binding capacity may be attributed to 
structural or polarity changes induced by the presence of RGD. It is important to 
mention here that the experiments in the present manuscript were performed in absence 
of heparin. Then, we speculate that the mutation is disrupting an important region for 
growth factor binding in a heparin-independent manner. Although the global protein net 
charge did not vary, positive (Arg) and negative (Asp) charges were introduced in the 
HBII sequence that may produce changes in the protein tertiary structure. Next to the 
loop where we introduced the RGD sequence there is a PRARI sequence that may act as 
heparin-binding domain in a similar manner than the aforementioned PRRARV 
sequence. We postulate that there may be electric repulsion between the positive charges 
of the PRARI sequence and the Arg positive charge, which is the nearest amino acid in 
the three dimensional structure. However, further experiments should be performed to 
demonstrate this hypothesis.
Apart from the heparin and growth factor-binding capacity of the HBII domain, it has 
been observed that this fragment also participates in cell adhesion. The PRRARV 
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sequence and other residues located in the III14 module, including the PRARI sequence, 
have also been described to regulate actin assembly and focal contacts formation.37,38 
These sequences interact with cell surface proteoglycans, mainly syndecan-4, in a 
comparable way than heparin binding.23 Nonetheless, presence of HBII functionalized 
onto a surface is not enough for inducing focal adhesion formation and requires the 
presence of the CAS fragment from fibronectin.19 The introduction of RGD in the 
sequence of HBII not only preserved the syndecan-4 binding capacity of the native HBII 
but also stimulated the formation of focal adhesions at the spreading edges of cells, 
observed by both vinculin and integrin β1 staining. The capacity of the HBII-RGD 
fragment to specifically bind integrin α5β1, the main receptor of fibronectin and the 
most expressed extracellular matrix receptor in undifferentiated MSCs, was 
demonstrated by ELISA and western blot. The novel molecule may mediate the 
formation of focal adhesions via two pathways. First, presence of RGD could act in 
synergy with syndecan-4 through protein kinase C (PKC) signalling.39 And second, 
physical proximity of integrins and growth factors receptors, due to the growth factor 
binding capacity of HBII, may facilitate their reciprocal activation controlling signalling 
pathways that include focal adhesion formation.40,41 During the process of cell 
spreading, actin polymerization drives the assembly of early cell contacts to the ECM at 
the leading edge of cells.42 These early contacts then maturate into focal adhesions that 
act as cytoskeletal organizing centers.43 Thus, presence of RGD in the novel mutated 
HBII fragment stimulates not only focal adhesion formation but also to some extent 
actin cytoskeletal assembly compared to native HBII fragment.
Finally, we wanted to know if the RGD-mutated HBII still retained its cell 
differentiation and mineralization capacity after the modification. The inherent growth 
factor binding capacity of the HBII fragment from fibronectin is responsible for 
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mediating cell differentiation towards specific lineages. However, presence of CAS 
from fibronectin is required for the osteogenic differentiation.18,19 Herein, we 
demonstrated that insertion of the RGD motif in the HBII sequence improved the 
differentiation capacity of the native HBII fragment, as observed by increased 
osteogenic gene expressions. Noteworthy, mineralization, which is a potent indicator of 
MSCs differentiation into bone-forming cells, was also improved after the RGD 
mutation, being almost three times higher compared to the native HBII fragment and the 
CAS70-HBII30 mixture. RGD and growth factor binding sequences may act in synergy, 
both stimulating co-activation of integrin and growth factor receptors as explained 
above. It is important to highlight that osteogenic factors were not used in the present 
study and therefore osteogenic induction should be attributed to the binding of growth 
factors from the serum on the novel protein. In addition, to ensure that the novel protein 
binds growth factors without influencing their activity, we cultured cells in presence of 
BMP-2 for 2h. It was previously described that the HBII fragment did not influence the 
proliferative effect of different angiogenic factors on endothelial and smooth muscle 
cells.20 However, the authors did not demonstrate that HBII does not affect the activity 
of BMP-2. We observed that the increase of gene expressions obtained for the native 
HBII fragment was also noticed for the RGD-mutated fragment in presence of BMP-2. 
As observed in absence of BMP-2, gene expressions dramatically increased at earlier 
times of cell culture, a pattern also observed when cells are treated with soluble BMP-
2.44-47 We speculate that gene expression is induced by the attraction of BMP-2 by the 
native and mutated HBII fragments and therefore it is not strange to observe similar 
patterns compared to other BMP-2-treatment studies. Then, gene expression results 
demonstrate the ability of the RGD-mutated HBII functionalized Ti to retain active 
BMP-2 molecules thereby acting as promising osteogenic surfaces.
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A novel recombinant protein fragment has been generated by DNA mutation 
introducing an RGD motif into the HBII sequence of fibronectin. The novel protein 
improves cell adhesion whereas it retains cell differentiation capability when 
immobilized on Ti compared to the native HBII fragment, being a promising candidate 
to improve bone tissue implant integration. The novel strategy to produce a gain-of-
function mutation into recombinant proteins opens a new window for engineering active 
molecules for regenerative medicine with virtually unlimited assembly design. 
Considering that the HBII fragment promiscuously binds several growth factors and the 
surprisingly high TGF-β1 binding capacity of the novel protein, the strategy could be 
adapted to biomaterials for other applications. In this regard, generation of a biomaterial 
with controlled spatiotemporal release of growth factors is of paramount interest in 
contrast to the use of biomaterials doped with growth factors.  Thus, integrin/growth 
factor receptor synergy is a key parameter for ongoing research in regenerative 
medicine.
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